CorMedix (NASDAQ:CRMD) reported a significant return to profitability for the fourth quarter on Thursday, as the commercial rollout of its lead product, DefenCath, gained momentum alongside contributions from its newly acquired Melinta Therapeutics portfolio.
Tango Therapeutics (NASDAQ:TNGX) reported fourth-quarter financial results on Thursday that surpassed Wall Street’s bottom-line expectations, supported by a significant extension of its capital reserves.
Immatics (NASDAQ:IMTX), a Tübingen, Germany-based clinical-stage biopharmaceutical company developing T cell receptor (TCR)-based immunotherapies for the treatment of solid tumors, on Thursday reported a net loss of $41.6 million for its fourth quarter ended December 31, 2025.
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported fourth-quarter financial results on Thursday that exceeded Wall Street expectations, driven by reduced operating expenses and licensing revenue.
Regenxbio (NASDAQ:RGNX) shares faced pressure Thursday after the biotechnology company reported fourth-quarter financial results that trailed Wall Street expectations on both the top and bottom lines.
MediWound (NASDAQ:MDWD), a biopharmaceutical developer focused on enzymatic therapeutics for tissue repair, reported fourth-quarter losses that were narrower than analysts had anticipated.
Bioventus (NASDAQ:BVS) reported a return to profitability for the full year 2025, supported by a strong fourth-quarter performance that saw organic revenue accelerate across its core healing therapies.
HUTCHMED (NASDAQ:HCM) reported a net income of $456.9 million for the full year 2025, a nearly 12-fold increase from the prior year, primarily driven by a one-time divestment gain and the continued global expansion of its oncology portfolio.
National Vision Holdings (NASDAQ:EYE) unveiled fourth-quarter and full-year 2025 results on Wednesday, marking its 12th consecutive quarter of positive comparable store sales growth as the optical retailer successfully navigates its post-Walmart transition.
TScan Therapeutics (NASDAQ:TCRX), a clinical-stage biopharmaceutical company developing T cell receptor (TCR)-engineered T cell therapies for the treatment of cancer, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update focused on progress across its allogeneic TCR-T platform.
Ocugen (NASDAQ:OCGN), a Malvern, Pennsylvania-based clinical-stage biotechnology company developing modifier gene therapies for ophthalmic and other diseases, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, alongside a business update highlighting progress across its three lead modifier gene therapy programs.
Cellectar Biosciences (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company specializing in radioconjugates, reported a significantly reduced net loss for 2025 as it transitioned its lead program, iopofosine I-131, into the final regulatory stages.
